GETI.B

187.6

+1.85%↑

CAMX

604

+2.11%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

CAMX

604

+2.11%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

CAMX

604

+2.11%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

CAMX

604

+2.11%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

CAMX

604

+2.11%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

RAY.B

325

0%↓

Search

BioArctic AB

Slēgts

180 2.04

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

176.1

Max

183.6

Galvenie mērījumi

By Trading Economics

Ienākumi

1.1B

1B

Pārdošana

1.2B

1.3B

P/E

Sektora vidējais

17.279

50.291

EPS

11.53

Peļņas marža

79.208

Darbinieki

116

EBITDA

-24M

-43M

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

425M

17B

Iepriekšējā atvēršanas cena

177.96

Iepriekšējā slēgšanas cena

180

BioArctic AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 26. jūn. 23:49 UTC

Peļņas

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

2025. g. 26. jūn. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

2025. g. 26. jūn. 21:30 UTC

Peļņas

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

2025. g. 26. jūn. 21:07 UTC

Peļņas

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

2025. g. 26. jūn. 23:49 UTC

Tirgus saruna

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

2025. g. 26. jūn. 23:39 UTC

Tirgus saruna

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

2025. g. 26. jūn. 23:34 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

2025. g. 26. jūn. 23:33 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

2025. g. 26. jūn. 23:32 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers Will No Longer Receive Earnings From BWP Management

2025. g. 26. jūn. 23:32 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

2025. g. 26. jūn. 23:31 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

2025. g. 26. jūn. 23:31 UTC

Iegādes, apvienošanās, pārņemšana

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

2025. g. 26. jūn. 23:30 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

2025. g. 26. jūn. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

2025. g. 26. jūn. 23:19 UTC

Iegādes, apvienošanās, pārņemšana

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

2025. g. 26. jūn. 22:06 UTC

Peļņas

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025. g. 26. jūn. 21:15 UTC

Peļņas

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

2025. g. 26. jūn. 21:07 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

2025. g. 26. jūn. 21:07 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

2025. g. 26. jūn. 21:07 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

2025. g. 26. jūn. 21:07 UTC

Peļņas

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

2025. g. 26. jūn. 21:06 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

2025. g. 26. jūn. 21:06 UTC

Iegādes, apvienošanās, pārņemšana

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

2025. g. 26. jūn. 21:06 UTC

Tirgus saruna

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

2025. g. 26. jūn. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025. g. 26. jūn. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

2025. g. 26. jūn. 20:52 UTC

Peļņas

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

2025. g. 26. jūn. 20:51 UTC

Peļņas

Correct: Nike 4Q Net $211M, Not $200M >NKE

2025. g. 26. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 26. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

BioArctic AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.